Make that 2 approved RNAi drugs at Alnylam after the FDA offers a speedy OK on ultra-rare disease drug
Seventeen years into the game, Alnylam’s pivot into commercial operations is picking up speed.
The bellwether biotech $ALNY has nabbed their second FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
